TY - JOUR
T1 - Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome
T2 - A Clinicopathological Case Series
AU - Asken, Breton M.
AU - Tanner, Jeremy A.
AU - Vandevrede, Lawren
AU - Casaletto, Kaitlin B.
AU - Staffaroni, Adam M.
AU - Mundada, Nidhi
AU - Fonseca, Corrina
AU - Iaccarino, Leonardo
AU - La Joie, Renaud
AU - Tsuei, Torie
AU - Mladinov, Miho
AU - Grant, Harli
AU - Shankar, Ranjani
AU - Wang, Kevin K.W.
AU - Xu, Haiyan
AU - Cobigo, Yann
AU - Rosen, Howie
AU - Gardner, Raquel C.
AU - Perry, David C.
AU - Miller, Bruce L.
AU - Spina, Salvatore
AU - Seeley, William W.
AU - Kramer, Joel H.
AU - Grinberg, Lea T.
AU - Rabinovici, Gil D.
N1 - Funding Information:
AMS has served as a consultant for Passage Bio and Takeda. JHK has provided consultation to Biogen. GDR has served as consultant for Eli Lilly, Eisai, Genentech, Roche, Johnson & Johnson , Merck, and Axon Neurosciences. LTG has received grant funding from Eli Lilly and consulted for CuraSen Inc. For the remaining authors, no competing financial interests exist.
Funding Information:
We thank the following funding sources who have supported out work: NIH ADRC (P30AG062422) to GDR/BLM and PPG (P01AG019724) to BLM; NIH (R01AG045611, U01AG057195) and the Rainwater Charitable Foundation to GDR; NIH (R01(s) AG032289 and AG048234) and Larry L. Hillblom Network Grant (2014-A-004-NET) to JHK; NIH (K24AG043435, U54NS100717) to LTG; NIH (R01AG072475) to KBC; NIH (K23AG061253) to AMS; NIH (R01AG062758) to DCP; NIH (R01NS110944), American Federation for Aging Research, and Global Brain Health Institute to RCG; and NIH (K99AG065501) and Alzheimer's Association (AARF-16-443577) to RLJ.
Publisher Copyright:
© 2022, Mary Ann Liebert, Inc., publishers 2022.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Traumatic encephalopathy syndrome (TES) criteria were developed to aid diagnosis of chronic traumatic encephalopathy (CTE) pathology during life. Interpreting clinical and biomarker findings in patients with TES during life necessitates autopsy-based determination of the neuropathological profile. We report a clinicopathological series of nine patients with previous repetitive head impacts (RHI) classified retrospectively using the recent TES research framework (100% male and white/Caucasian, age at death 49-84) who completed antemortem neuropsychological evaluations, T1-weighted magnetic resonance imaging, diffusion tensor imaging (n = 6), (18)F-fluorodeoxyglucose-positron emission tomography (n = 5), and plasma measurement of neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and total tau (n = 8). Autopsies were performed on all patients. Cognitively, low test scores and longitudinal decline were relatively consistent for memory and executive function. Medial temporal lobe atrophy was observed in all nine patients. Poor white matter integrity was consistently found in the fornix. Glucose hypometabolism was most common in the medial temporal lobe and thalamus. Most patients had elevated plasma GFAP, NfL, and total tau at their initial visit and a subset showed longitudinally increasing concentrations. Neuropathologically, five of the nine patients had CTE pathology (n = 4 "High CTE"/McKee Stage III-IV, n = 1 "Low CTE"/McKee Stage I). Primary neuropathological diagnoses (i.e., the disease considered most responsible for observed symptoms) were frontotemporal lobar degeneration (n = 2 FTLD-TDP, n = 1 FTLD-Tau), Alzheimer disease (n = 3), CTE (n = 2), and primary age-related tauopathy (n = 1). In addition, hippocampal sclerosis was a common neuropathological comorbidity (n = 5) and associated with limbic-predominant TDP-43 proteinopathy (n = 4) or FTLD-TDP (n = 1). Memory and executive function decline, limbic system brain changes (atrophy, decreased white matter integrity, hypometabolism), and plasma biomarker alterations are common in RHI and TES but may reflect multiple neuropathologies. In particular, the neuropathological differential for patients with RHI or TES presenting with medial temporal atrophy and memory loss should include limbic TDP-43. Researchers and clinicians should be cautious in attributing cognitive, neuroimaging, or other biomarker changes solely to CTE tau pathology based on previous RHI or a TES diagnosis alone.
AB - Traumatic encephalopathy syndrome (TES) criteria were developed to aid diagnosis of chronic traumatic encephalopathy (CTE) pathology during life. Interpreting clinical and biomarker findings in patients with TES during life necessitates autopsy-based determination of the neuropathological profile. We report a clinicopathological series of nine patients with previous repetitive head impacts (RHI) classified retrospectively using the recent TES research framework (100% male and white/Caucasian, age at death 49-84) who completed antemortem neuropsychological evaluations, T1-weighted magnetic resonance imaging, diffusion tensor imaging (n = 6), (18)F-fluorodeoxyglucose-positron emission tomography (n = 5), and plasma measurement of neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and total tau (n = 8). Autopsies were performed on all patients. Cognitively, low test scores and longitudinal decline were relatively consistent for memory and executive function. Medial temporal lobe atrophy was observed in all nine patients. Poor white matter integrity was consistently found in the fornix. Glucose hypometabolism was most common in the medial temporal lobe and thalamus. Most patients had elevated plasma GFAP, NfL, and total tau at their initial visit and a subset showed longitudinally increasing concentrations. Neuropathologically, five of the nine patients had CTE pathology (n = 4 "High CTE"/McKee Stage III-IV, n = 1 "Low CTE"/McKee Stage I). Primary neuropathological diagnoses (i.e., the disease considered most responsible for observed symptoms) were frontotemporal lobar degeneration (n = 2 FTLD-TDP, n = 1 FTLD-Tau), Alzheimer disease (n = 3), CTE (n = 2), and primary age-related tauopathy (n = 1). In addition, hippocampal sclerosis was a common neuropathological comorbidity (n = 5) and associated with limbic-predominant TDP-43 proteinopathy (n = 4) or FTLD-TDP (n = 1). Memory and executive function decline, limbic system brain changes (atrophy, decreased white matter integrity, hypometabolism), and plasma biomarker alterations are common in RHI and TES but may reflect multiple neuropathologies. In particular, the neuropathological differential for patients with RHI or TES presenting with medial temporal atrophy and memory loss should include limbic TDP-43. Researchers and clinicians should be cautious in attributing cognitive, neuroimaging, or other biomarker changes solely to CTE tau pathology based on previous RHI or a TES diagnosis alone.
KW - Biomarker
KW - Chronic traumatic encephalopathy
KW - Concussion
KW - Hippocampal sclerosis
KW - Limbic-predominant age-related tdp-43 encephalopathy
KW - Traumatic encephalopathy syndrome
UR - http://www.scopus.com/inward/record.url?scp=85137137823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137137823&partnerID=8YFLogxK
U2 - 10.1089/neu.2022.0060
DO - 10.1089/neu.2022.0060
M3 - Article
C2 - 35481808
AN - SCOPUS:85137137823
VL - 39
SP - 1195
EP - 1213
JO - Central Nervous System Trauma
JF - Central Nervous System Trauma
SN - 0897-7151
IS - 17-18
ER -